Herbals LLC has issued a nationwide recall of all lots of Vail-Bon Jie Yang Wan  supplement capsules due to the presence of ...

Dexamethasone can be an effective adjunct to opioid therapy for pain management during the perioperative period in pediatric ...

Isatuximab (Sarclisa) with bortezomib, lenalidomide, and dexamethasone (VRd) is now an approved option for adults who cannot ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

The Food and Drug Administration (FDA) has approved Sarclisa (isatuximab-irfc) with Velcade (bortezomib), Revlimid ...

Since an initial FDA go-ahead in 2020, Sanofi’s Sarclisa has been specifically approved for patients with previously treated ...

Johnson & Johnson (NYSE:JNJ) announced that a Phase 2 open-label trial for its lung cancer therapy Rybrevant reached the ...

Janssen-Cilag International NV, a Johnson & Johnson company (JNJ), announced results from the open-label Phase 2 SKIPPirr study, ...

Pretreatment with dexamethasone significantly reduced infusion-related reactions in patients receiving amivantamab for advanced lung cancer, according to findings from the SKIPPirr study.

Sanofi said the Food and Drug Administration has approved Sarclisa as a first line combined treatment option for adult patients with newly diagnosed multiple myeloma who aren't eligible for autologous ...

The NDA includes a combination of Blenrep with bortezomib plus dexamethasone (BorDex) or pomalidomide plus dexamethasone ...

The approval is supported by data from the phase 3 IMROZ study which demonstrated superior progression-free survival with ...